Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

Abstract

5,6-Dimethylxanthenone-4-acetic acid, synthesised in this laboratory, reduces tumour blood flow, both in mice and in patients on Phase I trial. We used TUNEL (TdT-mediated dUTP nick end labelling) assays to investigate whether apoptosis induction was involved in its antivascular effect. 5,6-Dimethylxanthenone-4-acetic acid induced dose-dependent apoptosis in vitro in HECPP murine endothelial cells in the absence of up-regulation of mRNA for tumour necrosis factor. Selective apoptosis of endothelial cells was detected in vivo in sections of Colon 38 tumours in mice within 30 min of administration of 5,6-Dimethylxanthenone-4-acetic acid (25 mg kg −1 ). TUNEL staining intensified with time and after 3 h, necrosis of adjacent tumour tissue was observed. Apoptosis of central vessels in splenic white pulp was also detected in tumour-bearing mice but not in mice without tumours. Apoptosis was not observed in liver tissue. No apoptosis was observed with the inactive analogue 8-methylxanthenone-4-acetic acid. Positive TUNEL staining of tumour vascular endothelium was evident in one patient in a Phase I clinical trial, from a breast tumour biopsy taken 3 and 24 h after infusion of 5,6-Dimethylxanthenone-4-acetic acid (3.1 mg m −2 ). Tumour necrosis and the production of tumour tumour necrosis factor were not observed. No apoptotic staining was seen in tumour biopsies taken from two other patients (doses of 3.7 and 4.9 mg m −2 ). We conclude that 5,6-Dimethylxanthenone-4-acetic acid can induce vascular endothelial cell apoptosis in some murine and human tumours. The action is rapid and appears to be independent of tumour necrosis factor induction. British Journal of Cancer (2002) 86 , 1937–1942. doi: 10.1038/sj.bjc.6600368 www.bjcancer.com © 2002 Cancer Research UK

The host STING pathway at the interface of cancer and immunity

“…DMXAA was previously known for its antivascular properties derived from a direct effect on tumor endothelial cells (79) or an indirect effect on macrophages as result of the induction TNF-α and NO generation by tumor-associated macrophages (TAM) (80,81). DMXAA also induced repolarization of M2-like macrophages to an M1-like phenotype in a mouse model of non-small cell lung carcinoma (NSCLC) (82); a similar activity conferred by treatment with a synthetic CDN was recently shown (83).…”

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

“…The tumour-VDA, ASA404, induces apoptosis of tumour vascular endothelial cells and cytokine production, leading to tumour vascular collapse (Ching et al, 2002;Baguley, 2003;Tozer et al, 2005). In animal models, this culminates in extensive tumour necrosis predominantly within the tumour core (Zwi et al, 1994;Laws et al, 1995;Ching et al, 1999Ching et al, , 2004Joseph et al, 1999).…”

Tumor Vascular Response to Photodynamic Therapy and the Antivascular Agent 5,6-Dimethylxanthenone-4-Acetic Acid: Implications for Combination Therapy

“…A wide variety of biological responses ranging from cytokine induction to activation of macrophage and natural killer cell activity have also been associated with DMXAA (11). The antitumor and antivascular effects of DMXAA seem mediated through a combination of direct effects of the drug on tumor vascular endothelial cells (12) and indirect effects through the induction of tumor necrosis factor-a (TNF-a; ref. 13), serotonin (14), IFN-inducible protein 10 (15), and nitric oxide (16).…”